Enimmune Corporation

NT$13.75As of Sun 8 Nov 2026, 12:00 UTC
TPEx:6564Healthcare
Country Taiwan
PE (Fwd) •••
TSR 8Y CAGR (7.16%)
Div yield —
ROE (74.45%)
Biotechnology
Beta (5Y) 0.25
PE TTM —
TSR TTM (33.63%)
Mkt cap NT$991.8M
ROIC (23.84%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$14
(0.30%)
(72.75%)
Hold 3|1|6|6|6
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.15
0.14
0.14
0.13
4.66%
5.08%
2.36%
(9.40%)
RevenueNT$M
77.37
77.29
81.47
79.23
8.54%
9.68%
10.34%
7.68%
Peers (US$29.85M)
Cap (US$)
PE
30.17M
—
29.70M
15.30x
Capital
TTM
5Y
10Y
Leveragex
0.893
(0.049)
(0.048)
EBIT/Intx
0.180
0.059
0.068
Own earn%
27.90
(107.69)
(105.90)
Sh yield%
13.17
27.25
31.79
Owners
Insiders/Inst%
10.12
23.15
Short interest%
1.46
SBC / revenue%
0.99
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
24
Op margin range%
6–11
$1 testx
—
Incr. ROIC%
1